Galapagos

Galapagos is a Mechelen, Belgium-based pharmaceutical research and biotechnology company that develops innovative medicines for unmet medical needs using an adenovirus-based drug discovery platform. The publicly traded enterprise initially secured $26.1 million across 21 early funding rounds before raising $316.7 million during its May 2015 initial public offering on the NASDAQ. The firm generates revenue through extensive research and development collaborations, most notably establishing a major strategic partnership with Gilead Sciences to advance treatments like filgotinib. Expanding its clinical pipeline, the corporation completed the acquisitions of CellPoint for €125 million and AboundBio for $14 million in June 2022, while recently adding EcoR1 Capital executive Oleg Nodelman to its board of directors. Galapagos was originally established in 1999 as a joint venture between Crucell and Tibotec by co-founders Onno van de Stolpe and Paul Stoffels.